• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Comprehensive evaluation of the cytotoxic T-lymphocyte antigen-4 gene polymorphisms in risk of bone sarcoma.

作者信息

Liu Shouying, Geng Peiliang, Cai Xu, Wang Jifang

机构信息

1 Department of Orthopedics, Chinese PLA General Hospital , Beijing, People's Republic of China .

出版信息

Genet Test Mol Biomarkers. 2014 Aug;18(8):574-9. doi: 10.1089/gtmb.2014.0023. Epub 2014 Jul 7.

DOI:10.1089/gtmb.2014.0023
PMID:25000484
Abstract

BACKGROUND

Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is a critical immunoregulatory molecule that attenuates the antitumor response by elevating the T-cell activation threshold, thus inducing occurrence of cancer.

OBJECTIVE

Several studies have reported the associations of CTLA-4 polymorphisms and bone sarcoma, but the findings remain to be further verified due to incomplete and limited evidence. The purpose of this study was to reevaluate the associations via a comprehensive meta-analysis.

METHODS

We searched Embase, Web of Knowledge, and PubMed and identified a total of four case-control studies fulfilling the inclusion criteria. Meta-analysis was conducted in all subjects without further stratified analyses. The associations were estimated by odds ratio (OR) along with 95% confidence interval (CI).

RESULTS

Analysis showed a significant association for the +49G>A polymorphism. This association was more pronounced in the homozygous model (OR=1.85; 95% CI: 1.40, 2.46; p=0.998 for heterogeneity) and the recessive model (OR=1.85; 95% CI: 1.41, 2.42; p=0.959 for heterogeneity). The allele model also demonstrated statistical evidence, indicating a moderately increased risk of bone sarcoma in relation to the +49>A polymorphism (OR=1.21; 95% CI: 1.08, 1.36; p=0.996 for heterogeneity). Conversely, neither an increase or nor a decrease was observed in the genotypes of -318C>T polymorphism.

CONCLUSIONS

Our meta-analysis provides evidence that support that the +49>A polymorphism, but not the -318C>T polymorphism, may be associated with elevated risk of bone sarcoma in Asians.

摘要

相似文献

1
Comprehensive evaluation of the cytotoxic T-lymphocyte antigen-4 gene polymorphisms in risk of bone sarcoma.
Genet Test Mol Biomarkers. 2014 Aug;18(8):574-9. doi: 10.1089/gtmb.2014.0023. Epub 2014 Jul 7.
2
Association of Cytotoxic T-lymphocyte Antigen-4 Polymorphisms with Malignant Bone Tumor Risk: A Meta-analysis.细胞毒性T淋巴细胞抗原4基因多态性与恶性骨肿瘤风险的关联:一项Meta分析
Asian Pac J Cancer Prev. 2016;17(8):3785-91.
3
Associations between the cytotoxic T lymphocyte antigen 4 polymorphisms and risk of bone sarcomas.细胞毒性T淋巴细胞抗原4基因多态性与骨肉瘤风险之间的关联。
Tumour Biol. 2015 Jan;36(1):227-31. doi: 10.1007/s13277-014-2621-6. Epub 2014 Sep 18.
4
Significant association between cytotoxic T lymphocyte antigen 4 +49G>A polymorphism and risk of malignant bone tumors.细胞毒性T淋巴细胞抗原4 +49G>A基因多态性与恶性骨肿瘤风险之间的显著关联。
Tumour Biol. 2013 Dec;34(6):3371-5. doi: 10.1007/s13277-013-0908-7. Epub 2013 Jul 31.
5
Cytotoxic T-lymphocyte antigen-4 genetic variants and risk of Ewing's sarcoma.细胞毒性T淋巴细胞抗原4基因变异与尤因肉瘤风险
Genet Test Mol Biomarkers. 2013 Jun;17(6):458-63. doi: 10.1089/gtmb.2012.0488. Epub 2013 Mar 12.
6
Cytotoxic T-lymphocyte antigen-4 polymorphisms and susceptibility to osteosarcoma.细胞毒性 T 淋巴细胞相关抗原-4 多态性与骨肉瘤易感性的关系。
DNA Cell Biol. 2011 Dec;30(12):1051-5. doi: 10.1089/dna.2011.1269. Epub 2011 May 25.
7
Association between the Cytotoxic T-lymphocyte antigen 4 +49G > A polymorphism and cancer risk: a meta-analysis.细胞毒性 T 淋巴细胞相关抗原 4 +49G > A 多态性与癌症风险的关联:荟萃分析。
BMC Cancer. 2010 Oct 4;10:522. doi: 10.1186/1471-2407-10-522.
8
Cytotoxic T-lymphocyte antigen-4 +49G/A polymorphism is associated with increased risk of osteosarcoma.细胞毒性T淋巴细胞抗原4 +49G/A多态性与骨肉瘤风险增加相关。
Genet Test Mol Biomarkers. 2011 Jul-Aug;15(7-8):503-6. doi: 10.1089/gtmb.2010.0264. Epub 2011 Mar 31.
9
Associations between cytotoxic T-lymphocyte-associated antigen 4 gene polymorphisms and diabetes mellitus: a meta-analysis of 76 case-control studies.细胞毒性 T 淋巴细胞相关抗原 4 基因多态性与糖尿病的关联:76 项病例对照研究的荟萃分析。
Biosci Rep. 2019 May 15;39(5). doi: 10.1042/BSR20190309. Print 2019 May 31.
10
CD 152 gene polymorphisms and risk of osteosarcoma in Chinese population.中国人群中CD 152基因多态性与骨肉瘤风险
Tumour Biol. 2014 Jul;35(7):6809-14. doi: 10.1007/s13277-014-1891-3. Epub 2014 Apr 12.

引用本文的文献

1
Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment.调控骨肉瘤的免疫微环境:骨肉瘤治疗的前景
Bone Res. 2023 Feb 27;11(1):11. doi: 10.1038/s41413-023-00246-z.
2
Prognostic significance and therapeutic potentials of immune checkpoints in osteosarcoma.骨肉瘤中免疫检查点的预后意义及治疗潜力
EXCLI J. 2022 Jan 12;21:250-268. doi: 10.17179/excli2021-4094. eCollection 2022.
3
TIM-3 expression and its association with overall survival in primary osteosarcoma.TIM-3在原发性骨肉瘤中的表达及其与总生存期的关联。
Oncol Lett. 2019 Nov;18(5):5294-5300. doi: 10.3892/ol.2019.10855. Epub 2019 Sep 12.
4
T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities.基于T细胞的骨肉瘤免疫疗法:挑战与机遇
Front Immunol. 2016 Sep 14;7:353. doi: 10.3389/fimmu.2016.00353. eCollection 2016.
5
Strategies and developments of immunotherapies in osteosarcoma.骨肉瘤免疫治疗的策略与进展
Oncol Lett. 2016 Jan;11(1):511-520. doi: 10.3892/ol.2015.3962. Epub 2015 Nov 24.
6
Impact of MDM2 309T>G polymorphism on sarcomagenesis.MDM2基因309T>G多态性对肉瘤发生的影响。
Int J Clin Exp Med. 2015 Aug 15;8(8):12810-7. eCollection 2015.